The latest Investing Matters Podcast episode with Inclusive Asset Management's Alexandra McGuigan has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPureTech Share News (PRTC)

Share Price Information for PureTech (PRTC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 213.50
Bid: 213.50
Ask: 214.50
Change: 0.00 (0.00%)
Spread: 1.00 (0.468%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 213.50
PRTC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Peel Hunt picks 'doublers' for the next 2-3 years

Tue, 18th Dec 2018 11:09

(Sharecast News) - Peel Hunt has named 29 companies it believes will double in value in the next two to three years, including JD Sports, GoCompare and CMC Markets.In "Stock Ideas for 2019: Doublers", published on Tuesday, Peel Hunt conceded it was difficult to predict how Brexit will affect markets, and noted that the FTSE All Share was on track to record its worst annual performance this year since 2008.But it added: "There are always some stocks that are dancing to their own particular tune which could deliver some healthy returns."Peel Hunt has given spread betting firm CMC Markets, which has seen profitability hit by tighter regulations and lower volatility, a price target of 200p."We are confident CMC will ultimately benefit from the impending market consolidation, expansion of the ANZ deal and return of market volatility," it argued. "Relatively small moves should result in significant operating leverage." A target price of 200p is double the last closing price of 100p.It called GoCompare, the price comparison website, a "great stock to help savings", arguing: "The share price has halved since the summer as the market has become unsettled at the near-term revenue trend and the launch of the innovative Saving as a Service product Weflip. "This ignores the profit protection achieved by the improvement in marketing margin and the strong operating cash generation." The price target is 140p, against Monday's close of 69p.Despite the wider retail sector's bumpy performance, JD Sports is one of Peel Hunt's preferred stocks. "It ticks all the boxes: it is growing strongly and winning share in its core market and that is true both online and in store." Peel Hunt also pointed to an "aggressive" overseas expansion."JD has a strong record of delivering and bettering expectations and despite the conditions in the UK, we think that forecasts are at worse underpinned." It added that the current multiple of 11 x PE was "way too low" and the target price is 550p not quite double the latest close.Another retailer to get the nod was Joules. "Against the background of retail turmoil and profit warnings, Joules recently reported first-half group revenue growth of 17.6% with profits tracking slightly ahead of expectations." Peel Hunt is targeting a share price of 400p, against Monday's close of 210p.Clinical stage biopharmaceutical company Motif Bio could see its share price surge early next year, argued Peel Hunt, with the US Food and Drug Administration due to give possible approval to Motif's antibiotic iclaprim on 13 February. Currently trading at 26p, Peel Hunt is targeting a price of 95p.Another healthcare company is PureTech Health, which Peel Hunt argued was "very undervalued" despite being well capitalised. The shares currently trade at 178p but Peel Hunt is looking for 313p.At Ten Entertainment, owner of bowling allies, Peel Hunt is forecasting earnings will rise by more than 50% over the next three years - although it conceded there was an "upside risk to expansion, like-for-like sales and margin forecasts".Peel Hunt said of The AA: "While there are a number of routes that may lead to the share price doubling, the common feature is the delivery of current consensus expectations."Early progress has been encouraging and further reassurance at the pre-close will be a key catalyst."Nanoco was a tech pick, as its new facility to make cadmium-free quantum dots and nanomaterials for its large US customer should be completed by the end of 2018, with volume production expected in the first half of 2019."This should be transformative for the company given the rapid growth in the sensor market," said Peel Hunt's analysts, with industry forecasts is for the 3D imaging & sensing market to increase from $2bn in 2017 to close to $10bn in 2020 and over $18bn by 2023, as Gartner calculated that around 40% of smartphones will have 3D sensors by 2021. The target price is 67p.Other companies highlighted by Peel Hunt included Eland Oil and Gas, Kaz Minerals, Manx Telecom, Polar Capital and Renold.
More News
11 Apr 2024 13:01

US FDA hands fast track to PureTech head and neck cancer treatment

(Alliance News) - PureTech Health PLC on Thursday said that its LYT-200 cancer treatment has received a significant endorsement from the US drugs regulator.

Read more
9 Apr 2024 11:33

PureTech Health CEO Zohar moves to head-up portfolio firm Seaport

(Alliance News) - PureTech Health PLC on Tuesday said its founding chief executive officer, Daphne Zohar, will shift to become CEO of Seaport Therapeutics, a biopharmaceutical company founded by PureTech.

Read more
9 Apr 2024 07:48

PureTech founder steps down as CEO to lead SeaPort spin-off

(Sharecast News) - Clinical-stage biotherapeutics group PureTech has announced that its founding chief executive is to step down to lead SeaPort Therapeutics, a PureTech company she founded that has just raised $100m in Series A financing.

Read more
19 Mar 2024 16:57

LONDON MARKET CLOSE: European large-caps rise on eve of Fed decision

(Alliance News) - Blue-chip stock prices in Europe closed higher on Tuesday, showing little signs of nerves ahead of Wednesday's Federal Reserve decision and UK inflation reading.

Read more
19 Mar 2024 11:16

PureTech shares jump on USD100 million tender offer proposal

(Alliance News) - PureTech Health PLC on Tuesday said it plans to return USD100 million to shareholders with a tender offer, starting after it publishes its annual report in April.

Read more
19 Mar 2024 09:46

Puretech Health proposes $100m capital return

(Sharecast News) - Biotherapeutics company PureTech Health has proposed a capital return of $100.0m to its shareholders by way of a tender offer.

Read more
13 Mar 2024 12:27

PureTech Health celebrates drug designation for LYT-200 from US FDA

(Alliance News) - PureTech Health PLC on Wednesday touted the efficacy of its acute myeloid leukaemia therapy, after securing a regulatory designation from the US Food & Drug Administration.

Read more
27 Feb 2024 11:28

PureTech notes positive results from Shionogi's EndeavorRx ADHD trial

(Alliance News) - PureTech Health PLC on Tuesday noted that its founded entity, Akili Inc, has announced positive results from a phase 3 clinical trial of EndeavorRx for children with attention deficit hyperactivity disorder in Japan.

Read more
20 Dec 2023 09:53

PureTech makes strong progress, expects "multiple catalysts" next year

(Alliance News) - PureTech Health PLC on Wednesday said it made "strong strategic and clinical progress" in 2023, and predicted "a productive and exciting" tear to come.

Read more
1 Dec 2023 14:29

TRADING UPDATES: N4 launches investor hub; Capricorn production falls

(Alliance News) - The following is a round-up of trading updates by London-listed companies, issued on Wednesday, Thursday and Friday and not separately reported by Alliance News:

Read more
17 Nov 2023 09:44

IN BRIEF: PureTech hails schizophrenia trial results for Karuna drug

PureTech Health PLC - Boston, Massachusetts-based FTSE 250 biotechnology company - Founded entity Karuna Therapeutics reports "positive results" from Phase 1b trial evaluating the effects of xanomeline-trospium, brand name KarXT, on 24-hour ambulatory blood pressure in adults with schizophrenia. Karuna says KarXT does not cause clinically meaningful blood pressure increases, with an average change from baseline at week eight of minus 0.59 mmHg or millimetre of mercury. Other vital signs like average diastolic blood pressure and heart rate were consistent with previous KarXT trials in schizophrenia. Adds that KarXT was generally well-tolerated, and side effects remained consistent with prior trials under the Emergent programme. Karuna in late September announced its application to the US Food & Drug Administration for approval of KarXT to treat schizophrenia; if successful, it will be PureTech's third therapeutic candidate to gain FDA approval. KarXT is also in development to treat psychosis associated with Alzheimer's disease.

Read more
17 Nov 2023 07:58

LONDON BRIEFING: UK retail sales fall; AstraZeneca gets US approval

(Alliance News) - Stock prices in London are still set to open higher on Friday, despite October retail sales figures for the UK disappointing shortly before the opening bell.

Read more
14 Nov 2023 10:59

PureTech Health celebrates positive results in Phase 2 anxiety trial

(Alliance News) - PureTech Health PLC on Tuesday said its therapeutic LYT-300 achieved its primary endpoint for acute anxiety reduction, in a Phase 2a trial using healthy volunteers.

Read more
11 Oct 2023 14:22

IN BRIEF: PureTech's LYT-100 shows 50% improvement to key adverse events

PureTech Health PLC - Boston-based biotechnology company - Says LYT-100 trial shows around 50% improvement in gastrointestinal and central nervous system related adverse events in adults suffering from idiopathic pulmonary fibrosis compared to US Food & Drug Administration-approved pirfenidone. Adds data shows higher dose of LYT-100 well-tolerated with no additional incidence of GI or CNS AEs when titrated up from 550 milligrams dosage.

Read more
4 Oct 2023 13:55

PureTech Health subsidiary receives fast track designation for VE202

(Alliance News) - PureTech Health PLC on Wednesday said its subsidiary Vedanta Biosciences has received fast-track designation for its VE202 treatment.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.